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INTRODUCTION
Trillions of microorganisms form the “natural flora” of the human body. These microorganisms
outnumber the host cells 10 to 1, essentially making humans a microbial ecosystem of sorts. Before
the advent of the high-throughput sequencing technologies such elusive microorganisms were
uncultivable and could not be studied using traditional microbiological techniques. However, since
the past decade, with the establishment of the Human Microbiome Project reference database in
2012, research in this area has grown logarithmically (Grogan, 2015). The human microbiota is
introduced frommother to the fetus and even infants, and remains with the growing individual for
the rest of his/her life, being effected by and also affecting the individual’s lifestyle, food habits, and
metabolism. Friendly microbes have been shown to protect from several diseases and a dysbiosis in
the microbiota has been linked to infections by pathogens, autoimmunity and lifestyle disorders.
The establishment of the brain-gut axis (reviewed in Carabotti et al., 2015) in the past few years
has even shown that gut microbiota and brain affect each other (Carabotti et al., 2015). A very
recent study established the missing link between the central nervous system (CNS) and the
immune system i.e., the CNS lymphatic vessels, thus completing the microbiota-neuronal-immune
system triangle (Louveau et al., 2015). Even stress, and behavioral changes can result in an altered
microbiota and vice–versa (Schmidt, 2015). This has brought microbiologists and neuroscientists
together to look into the probable mechanisms in which dysbiosis of gut microbiota may affect
development of neurodegenerative diseases and even neuronal autoimmunity.
Autoimmune diseases of both the central and the peripheral nervous system (PNS) have
been linked to microbiota, although the extent to which the link has been established is very
different. While some like multiple sclerosis (MS) has working mice-models, others like Guillain–
Barré syndrome (GBS), a rare autoimmune disorder of the PNS has no defined models, although
experimental autoimmune neuritis (EAN) may be used to study some aspects of GBS, especially
macrophage mediated demyelination (Kieseier et al., 2012). Even so, we have been warned against
the fallacies of studying such models in isolation, as there is no strict one model-one disorder
kind of relationship between human autoimmunity and mouse/rat model (Gold et al., 2000).
Since probiotics have been found to be useful in the treatment of autoimmune diseases like
Inflammatory Bowel Disease (IBD) (Sheil et al., 2007), type1 diabetes (Calcinaro et al., 2005) and
even extra-intestinal neuronal and systemic-autoimmune disorders like MS (Lavasani et al., 2010)
and systemic lupus erythematosus (SLE) (Manirarora et al., 2008; Alard et al., 2009), testing the
efficacy of probiotics in the treatment of GBS might offer a less invasive and more acceptable and
economical treatment alternative.
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PROBIOTICS MODULATE THE GUT
MICROBIOTA TO AFFECT THE HOST
IMMUNE SYSTEM
Altered gut microbiota or “gut dysbiosis” has been linked to
autoimmune responses both intra-intestinally as well as extra-
intestinally. Recently concluded and active research has helped
detail the mechanisms of interaction between the gut microbiota
and the immune system (Maynard et al., 2012). Attempts
to understand the mechanisms of restoration of healthy gut
microbiota (eubiosis) by probiotics has started to reveal the
complex interactions and signaling involved between the host
cells including components of the immune system, the probiotic
strain and the other commensal or pathogen residing in the host
system (Wagner et al., 2009; Wine et al., 2009; Maynard et al.,
2012; Bollrath and Powrie, 2013). It is generally accepted that
adaptive immunity to microbes may be mediated by Toll-like
receptors (TLRs), C-type lectin receptors (CLRs), and NOD-
like receptors (NLRs), which are present on the epithelium,
endothelium, and lymphoid tissue of the host. These receptors
might signal downstream depending upon the situation of
eubiosis (homeostasis)/dysbiosis (Walker, 2008; Maynard et al.,
2012). Traditionally, two T-cell fates have dominated the immune
system related signaling viz. T-helper cell (TH1) and TH2. TH1
type response is elicited on exposure to pathogens and leads to
their phagocytosis, causing inflammation to the surrounding host
tissue and even autoimmune responses. TH2 type of response
is elicited mainly on exposure to environmental cues and also
some pathogenic proteins, leading to the production of IgE
and release of histamines that counter TH1 response (Berger,
2000). Later studies have, however, revealed a much more
complex picture of autoimmunity and has introduced new types
of CD4+ T-cell viz. TH17 (Damsker et al., 2010) and CD25
+
FoxP3+ regulatory T-cells (Treg) (Sakaguchi et al., 2009). During
immune homeostasis the concentration of Interleukin (IL-10)
(also secreted by TH2 cells) secreting Treg cells dominate the
intestinal mucosa. In most of the autoimmune conditions, a
common feature seems to be diminished presence of Treg cells
in the intestinal mucosa of the host resulting in a shift toward
IL-17 secreting TH17 cells and this shift in the T-cell population
seems to be dependent on the intestinal cytokine Transforming
Growth Factor (TGF-β). Interestingly, in the face of pathogenic
infection or an inflammation caused by the resident microbiota,
the IL-10 secreting Treg cells are also converted to IL-17, Retinoic
acid-related Orphan Receptor (RORγT), and Interferon (IFN-γ)
producing TH17 cells (Xu et al., 2007) and vice–versa (Gagliani
et al., 2015). Research exploring the gut-brain axis has lead to
an understanding that altered gut microbiota plays a role not
only in gastrointestinal autoimmunity but also extra-intestinal
autoimmunity. Systemic and neuro-autoimmunities like SLE and
MS have been linked to gut dysbiosis, making a strong case for
linking GBS to altered microbiota.
Our current understanding of the link between gut eubiosis
and immune homeostasis, and the effect of probiotics on
the former have been reviewed elsewhere (Hemarajata and
Versalovic, 2013; Kueffel et al., 2013). Various studies have
already tipped the balance toward the use of probiotics
for providing relief in a number of diseases and disorders
including extra-intestinal autoimmunities. As briefly mentioned
above, a study has pointed toward the therapeutic effect of
probiotic consisting of a mixture of lactobacilli on experimental
autoimmune encephalomyelitis (EAE; an experimental model of
MS) through IL-10 secreting Treg cells (Lavasani et al., 2010).
In a later study, it has been shown that pro-inflammatory T-cell
response consisting of IL-17A and IFN-γ producing TH17 cells
caused EAE in germ-free mice upon infection from Segmented
Filamentous Bactria (SFB) (Lee et al., 2011), further linking
gut dysbiosis and neuronal autoimmunity. Immunopathology of
GBS too is complicated by TH17 cells and the corresponding
cytokines, thus making it a balance between TH1/TH17 and TH2,
although mechanistic details are yet to be elucidated (Liang et al.,
2012; Li et al., 2012, 2014). Functional aspects of TH17 cells
and associated cytokines and their rational drug targeting with
respect to GBS is discussed in some details elsewhere (Wang
et al., 2013; Wu et al., 2015). Studies on the lines of drug trials
have shown that in most stomach related ailments; probiotics
do confer a health benefit (Mack, 2005). Some small studies
in model organisms show that probiotics confer prophylactic
or curative benefit against diabetes, certain cancers, Human
Immunodeficiency Virus (HIV), rheumatoid arthritis, and MS
among several other conditions (Erickson and Hubbard, 2000;
Matsuzaki et al., 2007).
GUILLAIN–BARRÉ SYNDROME:
PROTOTYPE OF AN IMMUNE MEDIATED
PERIPHERAL NEUROPATHY
GBS is a post-infection autoimmune monophasic disorder of
the PNS and is characterized by acute flaccid paralysis. The
syndrome has variants categorized depending upon the kind
of neuropathy viz. demyelinating or axon degenerating. These
have been described in detail by Dimachkie and Barohn (2013)
and have been summarized in the form of a table in this
article (Table 1). The immunopathology of the GBS is not well
understood however it is known that the syndrome occurs post-
infection by Campylobacter jejuni (Kaldor and Speed, 1984;
Allos, 1997),Mycoplasma pneumonia (Goldschmidt et al., 1980),
certain Herpesviridae (Jacobs et al., 1998), HIV (Pontali et al.,
2011) and flu viruses (Sivadon-Tardy et al., 2009) or in some
cases after the administration of flu vaccine (Geier et al., 2003),
most probably due to an imbalance in the various T-helper
cell populations described above. Proinflammatory, TH1 type
cytokines like Tumor Necrosis Factor (TNF-α), IFN-γ, and IL-
1 have implicated in triggering mechanism of EAN/GBS. Other
proinflammatory cytokines like IL-12, TNF-α/β, and IL-2 are
also detected during the course of the disease progression. TH17
cytokines IL-17 and IL-22 have also been detected in the serum
of GBS patients thus confirming the role of TH17 mediated
pro-inflammatory response (Li et al., 2012). Interestingly,
proinflammatory cytokines IL-4, IL-5, and IL-6, may be produced
by cells expressing the rival TH2 phenotype, contributing to GBS.
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TABLE 1 | Variants of Guillain–Barré Syndrome.
GBS variant Symptoms Mechanism of autoimmunity Autoantigens implicated Remarks/references
AIDP Areflexia, mild sensory changes, distal
paresthesisas, loss of tendon reflexes,
ascending paralysis, respiratory failure
Macrophages, T-cell
mediated demyelination
Dimachkie and Barohn, 2013




GD1a, GM1, GM1b Shoenfeld and Meroni, 2012;
Dimachkie and Barohn, 2013
AMAN Accute, flaccid ascending paralysis, high
protein in the CSF, dysphagia, dysarthria, total






Discovered in China, less common
than AIDP in the West (Shoenfeld and
Meroni, 2012; Dimachkie and Barohn,
2013)
MFS Ophthalmoplegia, ataxia, areflexia Auto antibodies against
nerve gangliosides
GQ1b 5–10% cases in West but up to 25%
in Japan (Shoenfeld and Meroni,
2012; Dimachkie and Barohn, 2013)
However, TH2 type cytokines IL-10 and TGF-β are associated
with receding EAN/GBS symptoms (Zhu et al., 1998). Both T-
cell mediated and humoral immunity seems to be playing a role
in GBS. In Acute Inflammatory Demyelinating Polyneuropathy
(AIDP) variant, activated T-cells, upon antigen presentation by
macrophages, cross the blood-nerve barrier (BNB) and release
cytokines that activate endoneural macrophages, damaging the
compact myelin. Alternatively either by directly recognizing
a pathogenic epitope or elicited by T-cell, B-cells produce
antibodies to the cross-reactive axolemmal autoantigens and by
fixing a complement leads to the damage of Schwann cells and/or
axons, leading to Acute Motor Axonal Neuropathy (AMAN),
the more severe Acute Motor and Sensory Axonal Neuropathy
(AMSAN), or Miller Fisher Syndrome (MFS) (Hughes and
Cornblath, 2005). The most common autoantigens are GM1,
GM1a, and GD1a (Dimachkie and Barohn, 2013). Due to these
variants and their diverse pathology and pathogenesis, GBS
is now considered a group of heterogeneous conditions with
similar clinical phenotypes (Kieseier et al., 2012). GBS has
been considered a unique autoimmune disorder due to the
fact that unlike most other neuronal autoimmune disorders,
it is monophasic and that its occurrence has been found to
correspond to immunosuppression in the patient (Steiner et al.,
2010). The antecedent causative organisms mostly linked with
GBS include C. jejuni (≈38%) (Kaldor and Speed, 1984), M.
pneumonia (≈21%) (Sharma et al., 2011). Infections by most
or all of these agents are characterized by immunosuppression
either as a primary result of the infection or as a secondary
effect.
EUBIOTIC GUT TO CURE
GUILLAIN-BARRÉ SYNDROME
Infection by C. jejuni, M. pneumonia, and viruses mentioned
above also shows a differential effect on Treg and TH1 cell
populations with infected individuals showing a reduced Treg
cell presence (Steiner et al., 2010). Besides, there is evidence of C.
jejuni colonization being exacerbated by a shift in the microbiota
(characterized by increased Escherichia coli load in the gut)
upon infection by Toxolasma gondii (Haag et al., 2012) and
its alleviation by probiotic strain Lactobacillus helveticus strain
R0052 (Wine et al., 2009).With studies pointing toward probiotic
assisted increase in the population of anti-inflammatory Treg
cells (Smits et al., 2005; Kwon et al., 2010), and probiotics
modulating TH1(and TH17)/TH2 balance (Torii et al., 2007;
Tanabe, 2013) it may be worth testing whether this increase
in Treg cells reduces post infection autoimmunity in any way.
It may not be wrong to expect a Treg cell mediated immune
homeostasis of both the humoral (Wing and Sakaguchi, 2014)
and cellular kind (Shevach, 2009), produced as a result of
probiotic induced gut eubiosis.
CONCLUSION
GBS is a rare autoimmune disease effecting 2–4 people per
100,000. Being a rare condition it is neglected by the big
pharmaceutical companies, as well as academic researchers
searching for better treatments. Although the treatments
are available in the form of intravenous immunoglobulin
(IVIg) administration and plasma exchange, they become quite
expensive, especially in the developing countries. Added to it
the poor prognosis of the disease, there is a need for cheaper
alternatives to the currently available treatments. Probiotics have
been shown to be effective in treatment of several intestinal
and extra-intestinal autoimmunities, as they act by replenishing
the Treg cells in the immune system that have been shown
to promote the immune system homeostasis. There is ample
reason to believe that GBS also is a result of altered immune
homeostasis caused by infection due to an antecedent infection.
Thus, promoting the production of Treg cells may help cure
GBS by acting against both T- cell mediated and humoral
autoimmunity of the PNS.
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